Who owns Entrada Therapeutics, Inc. (TRDA)? Elite investor 13F holders
2 tracked elite investors reported holding Entrada Therapeutics, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | ENTRADA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1405760.00 USD | 191000.000000 | Shares | reduce | Original filing |
| D.E. Shaw | ENTRADA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 238442.00 USD | 32397.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.